Myelofibrosis is an uncommon type of bone marrow cancer and is
related to a group of blood cancers known as myeloproliferative
neoplasms. A simple blood test along with bone marrow biopsy can
diagnose myelofibrosis. Myelofibrosis is also known as chronic
myelosclerosis, agnogenic myeloid metaplasia, aleukemic
megakaryocytic myelosis, idiopathic myelofibrosis, and
leukoerythroblastosis. According to the report published by The
Leukemia & Lymphoma Society (LLS) in United States, myelofibrosis
occurs in about 1.5 out of every 100,000 people in the United States
annually. Patients above 50 years of age are more prone to the
disease, but it can occur at any age. Myelofibrosis affects women and
men with equal frequency, but in children, it is more likely to
affect girls more than boys. Though the treatment options available
for the myelofibrosis are scarce and almost all are suggestive, the
FDA approved (JAK inhibitor) drug-ruxolitinib forms a major line of
defense against myelofibrosis.
Report Overview @
https://www.transparencymarketresearch.com/myelofibrosis-market.html
Presently there are numerous research projects under examination that
are concentrating on developing specific treatment for myelofibrosis.
CTI BioPharma is studying oral pacritinib usage in myelofibrosis
treatment, a molecule - CYT387 is being developed by Gilead Sciences
for treating primary myelofibrosis, and Incyte Corporation is working
on a substitute dosing strategy of ruxolitinib on patients with
myelofibrosis. Plus, the innovator of ruxolitinib - Novartis is
constantly trying to come up with new usage of drug in various stages
of myelofibrosis.
The market is segmented on the basis of treatment type into blood
transfusion, chemotherapy, androgen therapy, and stem cell/bone
marrow transplantation. Based on end user, the market is further
classified into hospitals, clinics, and bone marrow transplant
centers. The market is also segmented on the basis of categories of
drugs available for treatment options such as hydroxyurea,
immunomodulators, JAK inhibitor (Ruxolitinib), and others.
In the report, Transparency Market Report (TMR) provides a detailed
analysis of drivers and restrictions in the global myelofibrosis
market. It also delivers insight to the segments and regions of the
market.
Request a Brochure of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17144
The occurrence of myelofibrosis is comparatively high in developing
economies, thereby increasing the demand for various treatment
options for myelofibrosis. The growth of the market is expected to
further rise due to heavy investments in research and development,
appropriate reimbursement conditions, and a large pool of patients
living with myelofibrosis. In addition, the growth can be attributed
to other factors such as lifestyle up-gradation, escalating smoking
population, and increasing incidence of genetic disorders. On the
contrary, limited awareness and high cost involved in treatment might
restrict the growth of the global myelofibrosis market.
Due to easy availability of chemotherapeutic agents, chemotherapy
segment is projected to contribute significantly to the revenue
generated by the market. The USFDA approved Ruxolitinib – the only
chemotherapeutic agent that is specifically administered for the
treatment of myelofibrosis, will give impetus to the global
myelofibrosis treatment market over the said period.
On the basis of geography, the global myelofibrosis market is
segmented into Europe, Asia Pacific, North America, and Rest of the
World. According to the report, North America is known to hold the
maximum market share, in terms of value. The growth of this region
can be attributed to the growing awareness, high prevalence of the
disease, higher percentage of income spent on healthcare compared to
other economies, and appropriate reimbursement circumstances. Asia
Pacific is expected to hold a large share in the market due to its
high geriatric population and increased disposable income, and
improving healthcare facilities.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=17144
The key players operating in the global myelofibrosis market are
Novartis, Roche, Merck & Co., Eli Lilly, Celgene, Amgen,
Bristol-Myers Squibb, Incyte Corporation, and Gilead Sciences.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment